Brief: Gracell Biotechnologies Presents Updated Data Of Deep And Durable Responses For Fastcar-T Gc012f
03/06/2023 19:27
June 3 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES PRESENTS UPDATED DATA OF DEEP AND
DURABLE RESPONSES FOR FASTCAR-T GC012F IN RELAPSED/REFRACTORY
MULTIPLE MYELOMA AT 2023 ASCO ANNUAL MEETING
* 93.1% (27/29) OVERALL RESPONSE RATE (ORR) FOR PATIENTS
TREATED
WITH GC012F
Source text for Eikon: ID:nPn8Db7DYa
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27